Obsessive Compulsive Disorder - Stanford CA

Summary:

Understanding How Ketamine Brings About Rapid Improvement in OCD Symptoms

Obsessive-Compulsive Disorder (OCD) is a chronic and disabling disorder that costs the economy over $2 billion annually and represents a significant public health problem. This study builds on our discovery that a potent NMDA receptor antagonist, ketamine, has rapid (hours) and robust therapeutic effects in OCD and will help us understand how ketamine works to relieve repetitive thoughts and behaviors.

Purpose: To understand how new drug brings about rapid improvement in OCD symptoms.

This clinical study is funded by the  by the National Institute of Mental Health (NIMH).

Qualified Participants Must:

• Be between 18 and 55 years of age
• Have a primary diagnosis of OCD
• Have sufficient severity of OCD symptoms
• Have the ability to tolerate a treatment-free period
• You have the capacity to provide informed consent

You cannot participate if:
• You have a psychiatric or medical conditions that make participation unsafe
• You are pregnant of nursing female
• You have major medical or neurological problem
• You have metallic device or dental braces

Qualified Participants May Receive:

The Stanford Translational OCD Research Program is looking for adults 18-55 years old with OCD to take part in a study providing these possible benefits:
Free diagnostic evaluation
Free test of your memory and attention
Compensation up to $400 after study completion
Your choice of free OCD psychotherapy or pharmacology after study completion